Karyopharm Therapeutics (KPTI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

KPTI Karyopharm Therapeutics

Watchlist

0.930
-0.043-4.39%

Close Jun 18 16:00 ET

0.960
+0.030+3.23%

Post 19:57 ET

115.89MMarket Cap-732P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3
RBC Capital analyst Brian Abrahams maintains $Karyopharm Therapeutics(KPTI.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 49
moomoo NewsJun 10 07:31 ET · Ratings
Karyopharm Therapeutics(KPTI.US) Director Sells US$785.03K in Common Stock
$Karyopharm Therapeutics(KPTI.US)$ Director PAKIANATHAN DEEPIKA sold 818.04K shares of common stock on Jun 5, 6, 7, 2024 at an average price of $0.9596 for a total value of $785.03K.Source: Announceme
moomoo NewsJun 7 20:00 ET
Karyopharm Therapeutics(KPTI.US) Director Sells US$880.69K in Common Stock
$Karyopharm Therapeutics(KPTI.US)$ Director PAKIANATHAN DEEPIKA sold 906.18K shares of common stock on May 31, Jun 3, 4, 2024 at an average price of $0.9719 for a total value of $880.69K.Source: Annou
moomoo NewsJun 4 19:31 ET
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanksJun 3 05:39 ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., June 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g
Karyopharm TherapeuticsJun 3 00:00 ET
Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024
Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024
BenzingaJun 2 14:37 ET

Comments

Jaguar8

Jun 2 01:46

NEWS

$Karyopharm Therapeutics(KPTI.US)$
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...